Indomethacin Extended-Release Capsules Recalled Due to Failed Dissolution Specifications
Glenmark Pharmaceuticals recalls 2,404 bottles of Indomethacin Extended-Release Capsules nationwide due to failed dissolution specifications that could affect medication effectiveness.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall with no reported illnesses, hospitalizations, or adverse health outcomes. The hazard—failed dissolution specifications affecting drug effectiveness—is a pharmaceutical quality issue without documented patient harm, consistent with precautionary recalls.
Plain-English summary
Glenmark Pharmaceuticals Inc., USA is recalling 2,404 bottles of Indomethacin Extended-Release Capsules, USP, 75 mg, distributed nationwide. The affected product includes 60-count bottles (NDC 68462-325-60) and 90-count bottles (NDC 68462-325-90) with Lot 17240105 and expiration date 12/31/2025.
The recall was initiated due to failed dissolution specifications. Dissolution test results for the affected lot were found to be below specification, which could affect the drug's therapeutic effectiveness.
Patients currently taking affected Indomethacin Extended-Release Capsules should consult their healthcare provider or pharmacist. Do not stop taking the medication without medical guidance. Contact Glenmark Pharmaceuticals or the FDA for information about whether your specific medication is affected.
The recalled product
- Product
- INDOMETHACIN (INDOMETHACIN)
- Brand
- INDOMETHACIN
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
- Category
- Drug
- Hazard
- failed-dissolution
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot#: 17240105
- Exp 12/31/2025
UPCs (1)
- 0368462325605
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · INDOMETHACIN
- HighFDA Recalls Indomethacin Extended-Release Capsules for Manufacturing Deviations
FDA (Drugs) · 2025-06-11
- ModerateIndomethacin Extended-Release Capsules Voluntarily Recalled for Manufacturing Deviations
FDA (Drugs) · 2025-05-28
- ModerateGlenmark Pharmaceuticals Recalls Indomethacin Capsules for Manufacturing Deviations
FDA (Drugs) · 2025-04-16
- HighPrescription Drug Indomethacin Recalled Due to Label Mix-Up
FDA (Drugs) · 2023-12-06
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27